a. The Global Anti-Phospholipid Syndrome Score [GAPSS].
b. The Adjusted Global Anti-Phospholipid Syndrome Score [aGAPSS].
Introduction:
a. The GAPSS risk score was developed to identify individuals with Anti-Phospholipid Syndrome [APS] at greater risk of thrombosis and/or pregnancy loss and is derived from a combination of
conventional cardiovascular risk factors and the autoimmune antibody profile - including both criteria and non-criteria aPL antibodies - see Comments.
In the original study, six variables:
- Arterial hypertension
- Hyperlipidaemia
- aCL antibodies
- LA
- Anti-β2GPI antibodies
- aPS/PT [antibodies to solid-phase Prothrombin (aPT) and to the phosphatidylserineprothrombin complex (aPS/PT)
..... were shown to be independent risk actors for thrombosis and pregnancy loss after multivariate analysis.
b. The Adjusted Global Anti-Phospholipid Syndrome Score [aGAPSS] excludes aPS/PT antibodies from the scoring algorithm recognising that these antibodies are not currently included
in the criteria for defining APS and not all laboratories routinely
test for aPS-PT antibodies.
The criteria that comprise the GAPSS score are summarised below: